Its lead product candidate, fluoroquinolone antibiotic FACTIVE tablet, is indicated for the treatment of community-acquired pneumonia and acute bacterial exacerbation of chronic bronchitis.
The company is developing an antibiotic candidate, Ramoplanin, which is in a phase II trial for the treatment of Clostridium difficile-associated diarrhea.
In addition, Oscient has various preclinical development programs, including an oral peptide deformylase inhibitor series for the potential treatment of respiratory tract infections, as well as the development of a FACTIVE intravenous formulation.
The company has alliances with AstraZeneca PLC; Schering-Plough, Ltd.
; bioMerieux Incorporated; Amgen, Inc.; and Wyeth for the discovery and development of therapeutics for chronic human diseases and certain infectious diseases.
The company was founded by Orrie M.
Friedman in 1961 under the name Collaborative Research, Inc.
It changed its name to Genome Therapeutics Corporation in 1994 and to Oscient Pharmaceuticals Corporation in 2004.
Oscient Pharmaceuticals is headquartered in Waltham, Massachusetts.
